NICE Approves Maintenance Rucaparib for Relapsed Ovarian Cancer

Oct 11, 2019 – The UK’s National Institute for Health and Care Excellence (NICE) has approved rucaparib for the maintenance treatment of patients with relapsed ovarian, fallopian tube, or peritoneal cancer that has responded to platinum-based chemotherapy. The decision is based on data from the phase III ARIEL3 trial, in which rucaparib led to a median progression-free survival (PFS) of 10.8 months compared with 5.4 months in patients who received placebo … (leggi tutto)